COVID 19 patents | Intellepedia

CPI(M) asks Government to issue compulsory license for Remdesivir, EPO creates search strategies to help fight against COVID-19 and more patent news

The CPI(M) has urged the Indian government to issue a compulsory license for Remdesivir to facilitate generic manufacturing. Additionally, the EPO has developed new patent search strategies for COVID-19, and an upcoming EUIPO-EPO conference will address intellectual property issues in additive manufacturing.

COVID crisis threatens Gilead’s patent on Remdesvir, EPO’s Enlarged Board of Appeal issues opinion on plant and animal patentability, India asks G20 to establish agreement enabling use of TRIPS flexibilities and other patent news

The post analyses patent law updates relating to COVID-19, including India’s push for TRIPS flexibilities and scrutiny of Gilead’s Remdesvir patent. It also covers the EPO’s stance on plant and animal patentability and new global initiatives in IP law enforcement.

Free Patent Filings for Open COVID Pledge Adopters

BananaIP is offering free patent and design filings in India for eligible COVID-19 related inventions if applicants adopt the Open COVID Pledge. This initiative aims to encourage innovation and open access to intellectual property in the fight against COVID-19.

Preference for Collaborative and Open COVID Innovation and Creativity

The post explores the preference for collaborative and open innovation during the COVID-19 crisis, detailing the decline in IP filings and the shift away from IP exclusivity. It analyses legal measures and global initiatives that promote sharing and accessibility for COVID-related technologies and research.